Pioglitazone significantly reduced tumor volume in male NSG mice bearing PC3 xenografts compared with vehicle control. In male C57BL/6J mice, Pioglitazone-supplemented HFD decreased epididymal fat adipocyte size by ∼36% compared with HFD alone; data were not shown. In male C57BL/6 mice receiving CDAHFD, Pioglitazone reduced serum ALT compared with CDAHFD plus vehicle control, with a reported value of 202.9 ± 16.5 U/L. [1,2,3]
Reduced tumor volume in a mouse xenograft model
Animal study · mouse xenograft experiment of PC3 cells in male NSG mice [1]
Male NSG mice bearing PC3 xenografts received Pioglitazone at 10 mg/kg daily by oral gavage. Pioglitazone significantly reduced tumor volume compared with vehicle control.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- daily
- Vehicle
- 20% hydroxypropyl-beta cyclodextrin
- Pioglitazone 10 mg/kg
- Model: mouse xenograft experiment of PC3 cells in male NSG mice
Methods and source locations
Compound reported in the paper: Pioglitazone
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Xenograft (S142, S144); Results > Pioglitazone suppresses cell migration of PCa cells and growth of metastatic PC3 xenograft tumors (S253, S255, S267)
Tumor volume throughout the 14 days of treatment: Tumor volume throughout the 14 days of treatment; comparator: vehicle control (20 % hydroxypropyl-beta cyclodextrin) (n = 6) — Results > Pioglitazone suppresses cell migration of PCa cells and growth of metastatic PC3 xenograft tumors (S255, S267)
Pioglitazone 10 mg/kg · Materials and Methods > Xenograft (S144); Results > Pioglitazone suppresses cell migration of PCa cells and growth of metastatic PC3 xenograft tumors (S255)
Decreased adipocyte size during high-fat feeding
Animal study · Six-week-old male C57BL/6J mice [2]
Male C57BL/6J mice received HFD supplemented with Pioglitazone at 10 mg · kg−1 · day−1. Treatment decreased epididymal fat adipocyte size by ∼36% compared with HFD alone; data were not shown.
Conditions shared by the study groups
- Route
- HFD supplemented with pioglitazone
- Treatment course
- for the last 5 weeks of 17-week HFD treatment
- Pioglitazone 10 mg · kg−1 · day−1
- Model: Six-week-old male C57BL/6J mice
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Pioglitazone
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
RESEARCH DESIGN AND METHODS > Maintenance of mice. (S4, S6, S7); RESULTS > M1 macrophage markers were increased by high-fat feeding and decreased by pioglitazone treatment, while M2 macrophage markers were not. (S34, S35, S36)
average adipocyte size in epididymal fat tissue: average adipocyte size in epididymal fat tissue; comparator: HFD — RESULTS > M1 macrophage markers were increased by high-fat feeding and decreased by pioglitazone treatment, while M2 macrophage markers were not. (S35, S36)
Pioglitazone 10 mg · kg−1 · day−1 · RESEARCH DESIGN AND METHODS > Maintenance of mice. (S7); RESULTS > M1 macrophage markers were increased by high-fat feeding and decreased by pioglitazone treatment, while M2 macrophage markers were not. (S34, S36)
Reduced serum ALT in a dietary mouse model
Animal study · Male C57BL/6 mice; n = 9/gp [3]
Male C57BL/6 mice receiving CDAHFD were treated with Pioglitazone at 30 mg/kg by oral gavage once daily. Serum ALT was reduced compared with CDAHFD plus vehicle control, with a reported value of 202.9 ± 16.5 U/L.
Conditions shared by the study groups
- Route
- oral gavage
- Treatment course
- treatment was continued for 12 week duration by oral gavage once daily
- Pioglitazone 30 mg/kg
- Model: Male C57BL/6 mice; n = 9/gp
- Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Pioglitazone
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
MATERIALS AND METHODS > Animal experiments (S21, S23, S24, S26); RESULTS > Saroglitazar reverses CDAHFD‐induced NASH in C57BL/6 mice (S76); Figure 3 legend (S105); Table 1 legend (S120); Table 1 (T1.h1, T1.r2)
Serum ALT (U/L): Serum ALT (U/L); comparator: CDAHFD‐Vehicle Control — RESULTS > Saroglitazar reverses CDAHFD‐induced NASH in C57BL/6 mice (S76); Table 1 legend (S120); Table 1 (T1.h1, T1.r2)
Pioglitazone 30 mg/kg · MATERIALS AND METHODS > Animal experiments (S23, S24); RESULTS > Saroglitazar reverses CDAHFD‐induced NASH in C57BL/6 mice (S76); Table 1 legend (S120); Table 1 (T1.h1, T1.r2)